STOCK TITAN

[8-K] American Superconductor Corp Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) has filed a Form 144 to notify the SEC of an intended insider sale.

  • Shares to be sold: 64,508 common shares
  • Aggregate market value: $1,928,595.68
  • Approximate sale date: 07/30/2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Shares outstanding: 74,107,668

The shares were acquired the same day (07/30/2025) through the exercise of employee stock options under a registered plan and will be sold for cash. No other sales by this insider were reported in the past three months.

The proposed disposition equals roughly 0.09% of total shares outstanding, indicating a modest, routine-sized transaction rather than a large liquidation. The filer attests to having no undisclosed material adverse information and confirms compliance with Rule 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentato un Modulo 144 per informare la SEC di una vendita interna prevista.

  • Azioni da vendere: 64.508 azioni ordinarie
  • Valore di mercato complessivo: 1.928.595,68 $
  • Data approssimativa della vendita: 30/07/2025
  • Intermediario: Morgan Stanley Smith Barney LLC, New York
  • Azioni in circolazione: 74.107.668

Le azioni sono state acquisite lo stesso giorno (30/07/2025) tramite l’esercizio di opzioni azionarie per dipendenti nell’ambito di un piano registrato e saranno vendute per contanti. Negli ultimi tre mesi non sono state segnalate altre vendite da parte di questo insider.

La cessione proposta rappresenta circa il 0,09% del totale delle azioni in circolazione, indicando una transazione modesta e di routine piuttosto che una liquidazione importante. Il dichiarante conferma di non possedere informazioni materiali negative non divulgate e di rispettare la Regola 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentado un Formulario 144 para notificar a la SEC sobre una venta interna prevista.

  • Acciones a vender: 64,508 acciones ordinarias
  • Valor total de mercado: 1,928,595.68 $
  • Fecha aproximada de la venta: 30/07/2025
  • Corredor: Morgan Stanley Smith Barney LLC, Nueva York
  • Acciones en circulación: 74,107,668

Las acciones fueron adquiridas el mismo día (30/07/2025) mediante el ejercicio de opciones sobre acciones para empleados bajo un plan registrado y se venderán por efectivo. No se reportaron otras ventas por parte de este insider en los últimos tres meses.

La disposición propuesta equivale aproximadamente al 0,09% del total de acciones en circulación, lo que indica una transacción modesta y rutinaria en lugar de una liquidación significativa. El declarante certifica que no posee información material adversa no divulgada y confirma el cumplimiento con la Regla 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA)는 SEC에 예정된 내부자 주식 매각을 알리기 위해 Form 144를 제출했습니다.

  • 매도 예정 주식 수: 64,508 보통주
  • 총 시장 가치: $1,928,595.68
  • 예상 매도일: 2025년 7월 30일
  • 중개인: Morgan Stanley Smith Barney LLC, 뉴욕
  • 발행 주식 수: 74,107,668

주식은 같은 날(2025년 7월 30일) 직원 스톡옵션 행사로 취득되었으며, 등록된 계획 하에 현금으로 매도될 예정입니다. 지난 3개월 동안 이 내부자의 다른 매도 보고는 없었습니다.

제안된 처분은 전체 발행 주식의 약 0.09%에 해당하며, 이는 대규모 청산보다는 소규모의 일상적인 거래임을 나타냅니다. 제출자는 미공개 중대한 부정적 정보가 없음을 확인하며, Rule 10b5-1 준수를 증명합니다.

Kiniksa Pharmaceuticals International, plc (KNSA) a déposé un Formulaire 144 pour informer la SEC d’une vente interne prévue.

  • Actions à vendre : 64 508 actions ordinaires
  • Valeur marchande totale : 1 928 595,68 $
  • Date approximative de la vente : 30/07/2025
  • Intermédiaire : Morgan Stanley Smith Barney LLC, New York
  • Actions en circulation : 74 107 668

Les actions ont été acquises le même jour (30/07/2025) par l’exercice d’options d’achat d’actions pour employés dans le cadre d’un plan enregistré et seront vendues contre espèces. Aucune autre vente par cet initié n’a été signalée au cours des trois derniers mois.

La cession proposée représente environ 0,09 % du total des actions en circulation, ce qui indique une transaction modeste et de routine plutôt qu’une liquidation importante. Le déclarant atteste ne pas détenir d’informations défavorables importantes non divulguées et confirme sa conformité à la règle 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) hat ein Formular 144 eingereicht, um die SEC über einen geplanten Insider-Verkauf zu informieren.

  • Zu verkaufende Aktien: 64.508 Stammaktien
  • Gesamtmarktwert: 1.928.595,68 $
  • Ungefähres Verkaufsdatum: 30.07.2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Ausstehende Aktien: 74.107.668

Die Aktien wurden am gleichen Tag (30.07.2025) durch Ausübung von Mitarbeiteraktienoptionen im Rahmen eines registrierten Plans erworben und werden gegen Barzahlung verkauft. In den letzten drei Monaten wurden keine weiteren Verkäufe dieses Insiders gemeldet.

Die vorgeschlagene Veräußerung entspricht etwa 0,09 % der insgesamt ausstehenden Aktien und deutet auf eine kleinere, routinemäßige Transaktion statt auf eine größere Liquidation hin. Der Einreicher bestätigt, keine nicht offengelegten wesentlichen negativen Informationen zu besitzen und die Regel 10b5-1 einzuhalten.

Positive
  • None.
Negative
  • Insider plans to sell 64,508 shares (~0.09% of 74.1 M outstanding) valued at $1.93 M

Insights

TL;DR: Small insider sale (0.09% OS) worth $1.9 M; signals routine diversification, limited fundamental impact.

The Form 144 shows an insider intends to sell 64,508 newly-exercised option shares, worth about $1.93 million, through Morgan Stanley on 07/30/2025. Given 74.1 million shares outstanding, the sale is immaterial to float and does not suggest broad insider pessimism. Lack of prior 3-month sales and same-day option exercise point to liquidity/tax planning rather than a directional bet. Investors typically view such filings as neutral unless accompanied by larger cluster selling. I rate the filing neutral for valuation and trading outlook.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentato un Modulo 144 per informare la SEC di una vendita interna prevista.

  • Azioni da vendere: 64.508 azioni ordinarie
  • Valore di mercato complessivo: 1.928.595,68 $
  • Data approssimativa della vendita: 30/07/2025
  • Intermediario: Morgan Stanley Smith Barney LLC, New York
  • Azioni in circolazione: 74.107.668

Le azioni sono state acquisite lo stesso giorno (30/07/2025) tramite l’esercizio di opzioni azionarie per dipendenti nell’ambito di un piano registrato e saranno vendute per contanti. Negli ultimi tre mesi non sono state segnalate altre vendite da parte di questo insider.

La cessione proposta rappresenta circa il 0,09% del totale delle azioni in circolazione, indicando una transazione modesta e di routine piuttosto che una liquidazione importante. Il dichiarante conferma di non possedere informazioni materiali negative non divulgate e di rispettare la Regola 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentado un Formulario 144 para notificar a la SEC sobre una venta interna prevista.

  • Acciones a vender: 64,508 acciones ordinarias
  • Valor total de mercado: 1,928,595.68 $
  • Fecha aproximada de la venta: 30/07/2025
  • Corredor: Morgan Stanley Smith Barney LLC, Nueva York
  • Acciones en circulación: 74,107,668

Las acciones fueron adquiridas el mismo día (30/07/2025) mediante el ejercicio de opciones sobre acciones para empleados bajo un plan registrado y se venderán por efectivo. No se reportaron otras ventas por parte de este insider en los últimos tres meses.

La disposición propuesta equivale aproximadamente al 0,09% del total de acciones en circulación, lo que indica una transacción modesta y rutinaria en lugar de una liquidación significativa. El declarante certifica que no posee información material adversa no divulgada y confirma el cumplimiento con la Regla 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA)는 SEC에 예정된 내부자 주식 매각을 알리기 위해 Form 144를 제출했습니다.

  • 매도 예정 주식 수: 64,508 보통주
  • 총 시장 가치: $1,928,595.68
  • 예상 매도일: 2025년 7월 30일
  • 중개인: Morgan Stanley Smith Barney LLC, 뉴욕
  • 발행 주식 수: 74,107,668

주식은 같은 날(2025년 7월 30일) 직원 스톡옵션 행사로 취득되었으며, 등록된 계획 하에 현금으로 매도될 예정입니다. 지난 3개월 동안 이 내부자의 다른 매도 보고는 없었습니다.

제안된 처분은 전체 발행 주식의 약 0.09%에 해당하며, 이는 대규모 청산보다는 소규모의 일상적인 거래임을 나타냅니다. 제출자는 미공개 중대한 부정적 정보가 없음을 확인하며, Rule 10b5-1 준수를 증명합니다.

Kiniksa Pharmaceuticals International, plc (KNSA) a déposé un Formulaire 144 pour informer la SEC d’une vente interne prévue.

  • Actions à vendre : 64 508 actions ordinaires
  • Valeur marchande totale : 1 928 595,68 $
  • Date approximative de la vente : 30/07/2025
  • Intermédiaire : Morgan Stanley Smith Barney LLC, New York
  • Actions en circulation : 74 107 668

Les actions ont été acquises le même jour (30/07/2025) par l’exercice d’options d’achat d’actions pour employés dans le cadre d’un plan enregistré et seront vendues contre espèces. Aucune autre vente par cet initié n’a été signalée au cours des trois derniers mois.

La cession proposée représente environ 0,09 % du total des actions en circulation, ce qui indique une transaction modeste et de routine plutôt qu’une liquidation importante. Le déclarant atteste ne pas détenir d’informations défavorables importantes non divulguées et confirme sa conformité à la règle 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) hat ein Formular 144 eingereicht, um die SEC über einen geplanten Insider-Verkauf zu informieren.

  • Zu verkaufende Aktien: 64.508 Stammaktien
  • Gesamtmarktwert: 1.928.595,68 $
  • Ungefähres Verkaufsdatum: 30.07.2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Ausstehende Aktien: 74.107.668

Die Aktien wurden am gleichen Tag (30.07.2025) durch Ausübung von Mitarbeiteraktienoptionen im Rahmen eines registrierten Plans erworben und werden gegen Barzahlung verkauft. In den letzten drei Monaten wurden keine weiteren Verkäufe dieses Insiders gemeldet.

Die vorgeschlagene Veräußerung entspricht etwa 0,09 % der insgesamt ausstehenden Aktien und deutet auf eine kleinere, routinemäßige Transaktion statt auf eine größere Liquidation hin. Der Einreicher bestätigt, keine nicht offengelegten wesentlichen negativen Informationen zu besitzen und die Regel 10b5-1 einzuhalten.

false 0000880807 0000880807 2025-07-30 2025-07-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
 

The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
July 30, 2025
 
American Superconductor Corporation
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-19672
 
04-2959321
(State or other jurisdiction
 
(Commission
 
(IRS Employer
of incorporation)
 
File Number)
 
Identification No.)
 
114 East Main Street
Ayer, Massachusetts
 
01432
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code (978842-3000
 
Not Applicable
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
Common Stock, $0.01 par value per share
 
AMSC
 
Nasdaq Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
Item 2.02. Results of Operations and Financial Condition. 
 
On July 30, 2025, American Superconductor Corporation (the “Company”) announced its financial results for the first quarter ended June 30, 2025 of the Company's fiscal year 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
 
The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
 
Item 9.01. Financial Statements and Exhibits.
 
(d) Exhibits:
 
Exhibit
No.
Description
99.1
Press release issued by American Superconductor Corporation on July 30, 2025 (furnished, not “filed,” for purposes of Section 18 of the Exchange Act).
104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
AMERICAN SUPERCONDUCTOR CORPORATION
 
 
 
Date:
July 30, 2025
By:
/S/ JOHN W. KOSIBA, JR.
 
 
 
John W. Kosiba, Jr.
 
 
 
Senior Vice President and Chief Financial Officer
 
 

FAQ

How many KNSA shares are being sold under this Form 144?

64,508 common shares are slated for sale.

What is the aggregate market value of the planned Kiniksa insider sale?

The filing lists an aggregate value of $1,928,595.68.

When is the approximate sale date for the KNSA shares?

The filer indicates an approximate sale date of 07/30/2025.

What percentage of KNSA's outstanding shares does this sale represent?

The 64,508 shares equal roughly 0.09% of the 74,107,668 shares outstanding.

Were there any other insider sales reported in the past three months?

No. The Form 144 states "Nothing to Report" for the prior three-month period.

How were the shares acquired prior to the sale?

They were obtained via option exercises under a registered plan on 07/30/2025 for cash.
American Superconductor Corp

NASDAQ:AMSC

AMSC Rankings

AMSC Latest News

AMSC Latest SEC Filings

AMSC Stock Data

1.96B
41.74M
4.4%
71.76%
8.02%
Specialty Industrial Machinery
Motors & Generators
Link
United States
DEVENS